352 related articles for article (PubMed ID: 31953128)
1. Antifungal effects of statins.
Tavakkoli A; Johnston TP; Sahebkar A
Pharmacol Ther; 2020 Apr; 208():107483. PubMed ID: 31953128
[TBL] [Abstract][Full Text] [Related]
2. Are the Statins promising antifungal agents against invasive candidiasis?
Lima WG; Alves-Nascimento LA; Andrade JT; Vieira L; de Azambuja Ribeiro RIM; Thomé RG; Dos Santos HB; Ferreira JMS; Soares AC
Biomed Pharmacother; 2019 Mar; 111():270-281. PubMed ID: 30590315
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for statins in fungal infections?
Bergman PW; Björkhem-Bergman L
Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1391-400. PubMed ID: 24215244
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity of statins against Aspergillus species.
Qiao J; Kontoyiannis DP; Wan Z; Li R; Liu W
Med Mycol; 2007 Nov; 45(7):589-93. PubMed ID: 18033614
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.
Nyilasi I; Kocsubé S; Krizsán K; Galgóczy L; Papp T; Pesti M; Nagy K; Vágvölgyi C
Med Mycol; 2014 Feb; 52(2):140-8. PubMed ID: 24004389
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
Cabral ME; Figueroa LI; Fariña JI
Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
[TBL] [Abstract][Full Text] [Related]
7. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi.
Nyilasi I; Kocsubé S; Krizsán K; Galgóczy L; Pesti M; Papp T; Vágvölgyi C
FEMS Microbiol Lett; 2010 Jun; 307(2):175-84. PubMed ID: 20636975
[TBL] [Abstract][Full Text] [Related]
8. In vitro interactions between primycin and different statins in their effects against some clinically important fungi.
Nyilasi I; Kocsubé S; Pesti M; Lukács G; Papp T; Vágvölgyi C
J Med Microbiol; 2010 Feb; 59(Pt 2):200-205. PubMed ID: 19875509
[TBL] [Abstract][Full Text] [Related]
9. Fungal Infections as an Uprising Threat to Human Health: Chemosensitization of Fungal Pathogens With AFP From
Dhandapani K; Sivarajan K; Ravindhiran R; Sekar JN
Front Cell Infect Microbiol; 2022; 12():887971. PubMed ID: 35694549
[TBL] [Abstract][Full Text] [Related]
10. New antifungal agents.
Gupta AK; Tomas E
Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
[TBL] [Abstract][Full Text] [Related]
11. Alternative treatment of fungal infections: Synergy with non-antifungal agents.
Rossato L; Camargo Dos Santos M; Vitale RG; de Hoog S; Ishida K
Mycoses; 2021 Mar; 64(3):232-244. PubMed ID: 33098146
[TBL] [Abstract][Full Text] [Related]
12. Antifungal Drugs: The Current Armamentarium and Development of New Agents.
Robbins N; Wright GD; Cowen LE
Microbiol Spectr; 2016 Oct; 4(5):. PubMed ID: 27763259
[TBL] [Abstract][Full Text] [Related]
13. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
14. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
15. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes.
Galgóczy L; Lukács G; Nyilasi I; Papp T; Vágvölgyi C
Acta Biol Hung; 2010 Sep; 61(3):356-65. PubMed ID: 20724281
[TBL] [Abstract][Full Text] [Related]
16. The 3-hydroxy-3-methylglutaryl coenzyme-A reductases from fungi: a proposal as a therapeutic target and as a study model.
Andrade-Pavón D; Sánchez-Sandoval E; Rosales-Acosta B; Ibarra JA; Tamariz J; Hernández-Rodríguez C; Villa-Tanaca L
Rev Iberoam Micol; 2014; 31(1):81-5. PubMed ID: 24270073
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
18. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs.
Manzoni M; Rollini M
Appl Microbiol Biotechnol; 2002 Apr; 58(5):555-64. PubMed ID: 11956737
[TBL] [Abstract][Full Text] [Related]
19. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Galgóczy L; Papp T; Lukács G; Leiter E; Pócsi I; Vágvölgyi C
FEMS Microbiol Lett; 2007 May; 270(1):109-15. PubMed ID: 17302920
[TBL] [Abstract][Full Text] [Related]
20. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
